Given the potential role of CXCL5 in diabetic vasculopathy, future clinical study is indicated to elucidate if direct inhibition on systemic CXCL5 level may prevent the development of diabetic foot ulcer and improve wound healing in type 1 and type 2 diabetic patients. This evidence concerns the gene CXCL5 and diabetic foot.